Atopic Dermatitis
Conditions
Brief summary
investigate the effectiveness and safety of adding vitamin K2 at a dose of 45 mg/day for 12 weeks to conventional therapy for paediatric patients with moderate to severe atopic dermatitis according to SCORAD score
Detailed description
This was a multicentre, prospective, blind randomized. patients are randomized to either receive their conventional therapy alone or by adding vitamin k2 for 12 weeks. The primary outcome was to evaluate the impact of vitamin K2 on the severity of atopic dermatitis, as assessed by the SCORAD score at 12 weeks compared to baseline.
Interventions
DIETARY_SUPPLEMENTvit k2
Vitamin K2 is a fat-soluble vitamin essential for blood clotting, bone health, and heart health, found in animal products and fermented foods.
OTHERPlacebo
placebo
Sponsors
October 6 University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
* patients aged 6-12 years * moderate to severe AD according to SCORAD score
Exclusion criteria
* other cutaneous allergic diseases (urticaria, angioedema, anaphylaxis, contact dermatitis). * primary immunodeficiency (PID) with cutaneous allergic manifestations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to evaluate the impact of vitamin K2 on the severity of atopic dermatitis, as assessed by the SCORAD score | at baseline and after 3months |
Secondary
| Measure | Time frame |
|---|---|
| Examination of the skin for eczema distribution, extent and intensity and Complete systemic examination for different forms of allergic disorder. | 3months |
| Janus kinase (JAK) | Measured at baseline and after three months |
| Serum total IgE | At baseline and after three months |
| IL-13 | at baseline and after three months |
| lipid profile | at baseline and after three months |
Countries
Egypt
Outcome results
None listed